Studies on the interaction of T-cells with major histocompatibility complex class II antigens

Clinical Science

Volumn 92, Issue 1, 1997, Pages 25-36

  Warrens, Anthony N ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cd4; Major histocompatibility complex; Myoblasts; Polymorphism; T lymphocytes; Tolerance

Indexed keywords

CD4 ANTIGEN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; POLYPEPTIDE; T LYMPHOCYTE RECEPTOR;

ALPHA CHAIN; ANTIGEN PRESENTATION; ARTICLE; BETA CHAIN; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE CLONE; MYOBLAST; PHYSIOLOGY; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0031033451     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs0920025     Document Type: Article

References (86)

1. Campbell R, Trowsdale J. Map of the human MHC. Immunol Today 1993; 14: 349-52.
2. Schwartz RH. Immune response (Ir) genes of the murine major histocompatibility complex. Adv Immunol 1986; 38: 31-202.
3. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature (London) 1987; 329: 506-12.
4. Brown JH, Jardetzky TS, Gorga JC, et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DRI. Nature (London) 1993; 364: 33-9.
5. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature (London) 1987; 329: 512-18.
6. Stern L, Brown J, Jardetzky T, et al. Crystal structure of the human class II MHC protein HLA-DRI complexed with an influenza virus peptide. Nature (London) 1993; 368: 215-21.
7. Warrens A, Lombardi G, Lechler R. Presentation and recognition of alloantigens. In: Thomson A, Catto G, eds. Immunology of renal transplantation. London: Edward Arnold, 1993.
8. a-encoded antigens. Nature (London) 1988; 332: 40-5.
9. Kappler J, Roehm N, Marrack P. T cell tolerance by clonal elimination in the thymus. Cell 1987; 49: 273-80.
10. Von Boehmer H, Teh HS, Kisielow P. The thymus selects the useful, neglects the useless and destroys the harmful. Immunol Today 1989; 10: 57-61.
11. + T cells. Eur J Immunol 1992; 22: 1013-22.
12. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science (Washington DC) 1970; 169: 1042-9.
13. Lamb J, Skidmore B, Green N, Chiller J, Feldman M. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza haemagglutinin. J Exp Med 1983; 157: 1434-47.
14. Sidhu S, Deacock S, Bal V, Batchelor J, Lombardi G, Lechler R. Human T cells cannot act as autonomous antigen-presenting cells, but induce tolerance in antigen-specific and alloreactive responder cells. J Exp Med 1992; 176: 875-80.
15. Gaspari A, Jenkins M, Katz S. Class II MHC-bearing keratinocytes induce antigen-specific unresponsiveness in hapten-specific Th1 clones. J Immunol 1988; 141: 2216-20.
16. Bal V, McIndoe A, Denton G, et al. Antigen presentation by keratinocytes induces tolerance in human T cells. Eur J Immunol 1990; 20: 1893-7.
17. Markmann J, Lo D, Naji A, Palmer RD, Brinster RL, Heber-Katz E. Antigen presenting function of class II MHC expressing pancreatic beta islet cells. Nature (London) 1988; 336: 476-9.
18. Quill H, Schwartz RH. Stimulation of normal inducer T cell clones with antigen presented by purified 1a molecules in planar lipid membranes: specific induction of a long-lived state of proliferative nonresponsiveness. J Immunol 1987; 138: 3704-12.
19. De Magistris M, Alexander J, Coggeshall M, et al. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell 1992; 68: 625-34.
20. Geiger T, Gooding L, Flavell R. T-cell responsiveness to an oncogenic peripheral protein and spontaneous autoimmunity in transgenic mice. Proc Natl Acad Sci USA 1992; 89: 2985-9.
21. Rocha B, von Boehmer H. Peripheral selection of the T cell repenoire. Science (Washington DC) 1991; 251: 1225-8.
22. Moskophidis D, Lechner F, Pircher H, Zinkernagel R. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature (London) 1993; 362: 758-61.
23. Miller J, Heath W. Self ignorance in the peripheral T cell pool. Immunol Rev 1993; 133: 131-50.
24. Harding F, McArthur J, Gross J, Raulet D, Allison J. CD28-mediated signalling costimulates murine T cells and prevents the induction of anergy in T cell clones. Nature (London) 1992; 356: 607-9.
25. Tan P, Anasetti C, Hansen J, et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993; 177: 165-73.
26. Chen L, Ashe S, Brady W, et al. Costimulation of antitumor activity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093-102.
27. Liu Y, Jones B, Brady W, Janeway Jr C, Linsley P. Costimulation of murine CD4 T cell growth: cooperation between B7 and heat stable antigen. Eur J Immunol 1992; 22: 2855-9.
28. Tite J, Sloan A, Janeway Jr C. The role of L3T4 in T cell activation: L3T4 may be both an 1a binding protein and a receptor that transduces a negative signal. J Mol Cell Immunol 1986; 2: 179-90.
29. Koenig M, Hoffman E, Bertelson C, Monaco A, Feener C, Kunkel L. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary organisation of the DMD gene in normal and affected individuals. Cell 1987; 50: 509-17.
30. Partridge T. Myoblast transfer: a possible therapy for inherited myopathies. Muscle Nerve 1991; 14: 197-212.
31. Law P, Goodwin T, Fang Q, et al. Feasibility, safety, and efficacy of myoblast transfer therapy on Duchenne muscular dystrophy boys. Cell Transplantation 1992; 1: 235-44.
32. Tremblay J, Malouin F, Roy R, et al. Results of triple blind clinical study of myoblast transplantation without immunosuppressive treatment in young boys with Duchenne muscular dystrophy. Cell Transplant 1993; 2: 99-112.
33. Ascadi G, Dickson G, Love D, et al. Human dystrophin expression in mdx mice after intramuscular injection of DN A constructs. Nature (London) 1991; 352: 815-18.
34. Ragot T, Vincent N, Chafey P, et al. Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature (London) 1993; 361: 647-50.
35. Roy R, Dansereau G, Tremblay J, et al. Expression of major histocompatibility complex antigens on human myoblasts. Transplant Proc 1991; 23: 799-801.
36. Hardiman O, Faustman D, Li X, Sklar R, Brown Jr R. Expression of major histocompatibility complex antigens in clonally derived human myoblasts. Neurology 1993; 43: 604-8.
37. Warrens A, Zhang J, Sidhu S, et al. Myoblasts fail to stimulate T cells but induce tolerance. Int Immunol 1994; 6: 847-53.
38. Ansari A, Wang Y, Kanter K, Naucke N, Sell K. Indirect presentation of donor histocompatibility antigens contributes to the allogeneic response against human cardiac myocytes. J Heart Lung Transplant 1992; 11: 467-8.
39. Bodmer J, Marsh S, Albert E, et al. Nomenclature for factors of the HLA system, 1994. Tissue Antigens 1994; 44: 1-18.
40. Klein J, Figueroa F. Polymorphism of the mouse H-2 loci. Immunol Rev 1981; 60: 23-57.
41. Ehrich E, Devaux B, Rock E, Jorgensen J, Davis M, Chien Y. T cell receptor interactions with peptide/major histocompatibility complex (MHC) and superantigen/MHC ligands is dominated by antigen. J Exp Med 1993; 178: 713-22.
42. Tuosto L, Karr R, Fu X-T, et al. Different regions of the N-terminal domains of HLA-DRI influence recognition of individual peptide-DRI complexes. Hum Immunol 1994; 40: 312-22.
43. Chu Z-Y, Carswell-Crumpton C, Cole B, Jones P. The minimal polymorphism of class II Ea chains is not due to the functional neutrality of mutations. Immunogenetics 1994; 40: 9-20.
44. Jones P, Chu E-T, Nunez S. A novel form of polymorphism in MHC class II proteins. Proceedings of 8th International H-2/HLA workshop. Jekyl Island, Georgia, USA. 1992 [Abstract].
45. Barber LD, Bal V, Lamb JR, et al. Contribution of T cell-receptor contacting and peptide-binding residues of the class II molecule HLA-DR4 DwIO to serologic and antigen-specific T cell recognition. Hum Immunol 1991; 32: 110-18.
46. Warrens A, Jones M, Lechler R. Splicing by overlap extension by PCR using asymmetric amplification: an improved technique for the generation of hybrid proteins of immunological interest. Gene (In press).
47. Vordermeier H, Harris D, Roman E, Lathigra R, Moreno C, Ivanyi J. Identification of T cell stimulatory peptides from the 38-kDa protein of Mycobacterium tuberculosis. J Immunol 1991; 147: 1023-9.
48. d genes into L cells results in the surface expression of a functional mixed-isotype 1a molecule. Proc Natl Acad Sci USA 1986; 83: 3958-62.
49. Spencer JS, Kubo RT. Mixed isotype class II antigen expression. A novel class II molecule is expressed on a murine B cell lymphoma. J Exp Med 1989; 169: 625-40.
50. d mice. J Exp Med 1992; 175: 157-62.
51. Lotteau V, Teyton L, Burroughs D, Charron D. A novel HLA class II molecule (DRα-DQβ) created by mismatched isotype pairing. Nature (London) 1987; 329: 339-41.
52. Charron D, Hermans P, Lotteau V, et al. Interisotypic α- and β-chain assembly as a source of HLA class-II diversity. Immunol Res 1990; 9: 234-43.
53. Warrens A, Heaton T, Sidhu S, Lombardi G, Lechler R. Transfected murine cells expressing HLA class II can be used to generate alloreactive human T cell clones. J Immunol Methods 1994; 169: 25-33.
54. Trowsdale J, Ragoussis J, Campbell RD. Map of the human MHC. Immunol Today 1991; 12: 443-6.
55. Altmann DM, Sansom D, Marsh SGE. What is the basis of HLA-DQ association with autoimmune disease? Immunol Today 1991; 12: 267-70.
56. Merkenschlager M, Ikeda H, Wilkinson D, et al. Allorecognition of HLA-DR and -DQ transfectants by human CD45RA and CD45RO CCM T cells: repertoire analysis and activation requirements. Eur J Immunol 1991; 21: 79-88.
57. Lombardi G, Sidhu S, Daly M, Batchelor JR, Makoba W, Lechler RI. Are primary alloresponses truly primary? Int Immunol 1989; 2: 9.
58. Lombardi G, Sidhu S, Lamb JR, Batchelor JR, Lechler RI. Co-recognition of endogenous antigens with HLA-DRI by alloreactive human T cell clones. J Immunol 1989; 142: 753-9.
59. Greenstein J, Malissen B, Burakoff S. Role of L3T4 in antigen-driven activation of a class-I specific T cell hybridoma. J Exp Med 1985; 162: 369-74.
60. Gay D, Maddon P, Sekaly R, et al. Functional interaction between human T-cell protein CD4 and the major histocompatibility complex HLA-DR antigen. Nature (London) 1987; 328: 626-9.
61. Gay D, Buus S, Pasternak J, Kappler J, Marrack P. The T-cell accessory molecule CD4 recognizes a monomorphic determinant on isolated 1a. Proc Natl Acad Sci USA 1988; 85: 5629-33.
62. Doyle C, Strominger JL. Interaction between CD4 and class II MHC molecules mediates cell adhesion. Nature (London) 1987; 330: 256-9.
63. Clayton L, Sieh M, Pious D, Reinherz E. Identification of human CD4 residues affecting class II MHC versus HIV-1 gp120 binding. Nature (London) 1989; 339: 548-51.
64. Rosenstein Y, Burakoff S, Hermann S. HIV-gp120 can block CD4-class II MHC-mediated adhesion. J Immunol 1990; 144: 526-31.
65. Cosgrove D, Gray D, Dierich A, et al. Mice lacking MHC class II molecules. Cell 1991; 66: 1051-66.
66. + cells but markedly decreased helper cell activity in mice lacking CD4. Nature (London) 1991; 353: 180-4.
67. k hybrid molecules. J Immunol 1991; 147: 2034-40.
68. Ramesh P, Barber L, Batchelor R, Lechler R. Structural analysis of human anti-mouse H-2E xenorecognition: T cell receptor bias and impaired CD4 interaction contribute to weak xenoresponses. Int Immunol 1992; 4: 935-43.
69. 2 domain of major histocompatibility complex class II molecules. J Exp Med 1992; 175: 925-32.
70. König R, Huang L, Germain R. MHC class II interaction with CD4 mediated by a region analogous to the MHC class I binding site for CD8. Nature (London) 1992; 356: 796-8.
71. 2 domain of HLA-DR molecules. Nature (London) 1992; 356: 799-801.
72. Clayberger C, Lyu S-C, DeKruyff R, Parham P, Krensky A. Peptides corresponding to the CD8 and CD4 binding domains of HLA molecules block T lymphocyte immune responses in vitro. J Immunol 1994; 153: 946-51.
73. Nag B, Wada H, Passmore D, Clark B, Sharma S, McConnell H. Purified β-chain of MHC class II binds to CD4 molecules on transfected HeLa cells. J Immunol 1993; 150: 1358-64.
74. Schafer P, Pierce S. Evidence for dinners of MHC class II molecules in B lymphocytes and their role in low affinity T cell responses. Immunity 1994; 1: 699-707.
75. Davis S, Ward H, Puklavec M, Willis A, Williams A, Barclay A. High level expression in Chinese hamster ovary cells of soluble forms of CD4 T lymphocyte glycoprotein including glycosylation variants. J Biol Chem 1990; 265: 10410-18.
76. Langedijk J, Puijk W, van Hoorn W, Meloen R. Location of CD4 dimerization site explains critical role of CDR3-like region in HIV-1 infection and T-cell activation and implies a model for complex of coreceptor-MHC. J Biol Chem 1993; 268: 16875-8.
77. Lamarre D, Ashkenazi A, Fleury S, Smith D, Sekaly R, Capon D. The MHC-binding and gp120-binding functions of CD4 are separable. Science (Washington DC) 1989; 245: 743-6.
78. Bowman M, MacFerrin K, Schreiber S, Burakoff S. Identification and structural analysis of residues in the VI region of CD4 involved in interaction with human immunodeficiency virus envelope glycoprotein gp120 and class II major histocompatibiliry complex molecules. Proc Natl Acad Sci USA 1990; 87: 9052-6.
79. Fleury S, Lamarre D, Meloche S, et al. Mutational analysis of the interaction between CD4 and class II MHC: class II antigens contact CD4 on a surface opposite the gp120-binding site. Cell 1991; 66: 1037-49.
80. Piatier-Tonneau D, Gastinel L-N, Moussy G, et al. Mutations in the D strand of the human CD4 VI domain affect CD4 interactions with the human immunodeficiency virus envelope glycoprotein gp120 and HLA class II antigens similarly. Proc Natl Acad Sci USA 1991; 88: 6858-62.
81. Moebius U, Clayton L, Abraham S, et al. Human immunodeficiency virus gp120 binding C′C″ ridge of CD4 domain I is also involved in interaction with class II major histocompatibility complex molecules. Proc Natl Acad Sci USA 1992; 89: 12008-12.
82. Houlgatte R, Scarmato P, El Marhomy S, et al. HLA class II antigens and the HIV envelope glycoprotein GP120 bind to the same face of CD4. J Immunol 1994; 152: 4475-88.
83. Lamarre D, Capon D, Karp D, Gregory T, Long E, Sekaly R-P. Class II MHC molecules and the HIV gp120 envelope protein interact with functionally distinct regions of the CD4 molecule. EMBO J 1989; 8: 3271-7.
84. von Hoegen P, Miceli M, Tourvieille B, Schilham M, Parnes J. Equivalence of human and mouse CD4 in enhancing antigen responses by a mouse class II-restricted T cell hybridoma. J Exp Med 1989; 170: 1879-86.
85. König R, Shen X, Germain R. Involvement of both major histocompatibility complex class II α and β chains in CD4 function indicates a role for ordered oligomerization in T cell activation. J Exp Med 1995; 182: 779-87.
86. Barber LD, Lechler RI. Interactions between the amino-terminal domains of MHC class II molecules have a profound effect on serologic and T cell recognition: an analysis using recombinant HLA-DR/H-2E molecules. J Immunol 1991; 147: 2346-53.